Nasdaq Markets

The coronavirus pandemic has had a huge impact on people's lives, and the effects are going well beyond health. Millions of people have lost their jobs, at least temporarily, and there's huge uncertainty about when many will be able to go back to work.

Ford Motor (NYSE: F) has been preparing for a downturn for years. But not too many auto executives -- or auto investors -- ever expected to see what we've seen in the last few weeks: Factories shut down and employees sent home to wait out a virus pandemic. 

With the number of confirmed COVID-19 cases rising despite worldwide lockdowns and social distancing efforts, the biotech industry is taking action. In just two months since the first infection was reported in the U.S., the country’s total number of cases has surpassed both that of Italy and China, and the Trump administration is calling on names in the space to step in. The sector’s response? Challenge accepted.  

As the U.S. government pumped $8.3 billion into research as well as prevention efforts, several biotech companies have joined the fight against COVID-19. Among those battling the virus, one of TipRanks’ top five rated investing firms, Oppenheimer, recently highlighted two biotech heavyweights that have made notable strides in developing COVID-19 drugs. 

Bearing this in mind, we used TipRanks’ database to learn more about Oppenheimer’s picks. It turns out that each Buy-rated ticker has also received substantial support from other Wall Street analysts. Here’s the full rundown.  

Gilead Sciences (GILD)  

First up we have healthcare giant Gilead Sciences. After hosting key opinion leaders (KOLs), Dr. Mitchell Weinstein and Dr. Kashif Memon, Oppenheimer has come away more confident in the company’s long-term growth prospects.  

Weighing in on GILD for the firm, analyst Hartaj Singh points out that both of the KOLs believe “the first obstacle to overcome is the lack of rapid diagnostics, followed by a paucity of treatment options and lastly vaccines to prevent future outbreaks.” Additionally, the analyst argues that while current off-label treatments for COVID-19 such as chloroquine/hydroxychloroquine appear to be effective and well-tolerated, there is very little clinical evidence when it comes to this combination. As a result, the KOLs are open to all possible treatment options. 

Enter Gilead. The biotech name’s remdesivir (IV) drug was originally developed as an antiviral against Ebola, but is now being evaluated as a possible COVID-19 treatment. Even though it will be challenging to gear the therapy towards COVID-19, its mechanism of action (MOA) is promising, with the analyst eagerly awaiting Ebola NHP data and the data readout from the Phase 3 studies for mild/moderate and severe COVID-19 patients.  

It should also be noted that the KOLs stated statistical significance in the Phase 3 trials isn’t necessarily required to support the drug’s approval. “If neither Phase 3 trial hit statistical significance on primary measures, our KOLs indicated they would like to see improvements in various secondary measures and perhaps a trend improvement in the primary measure. Coupled with a benign safety profile, our KOLs still see a place for remdesivir in the current bare treatment armamentarium,” Singh explained. 

On top of this, GILD shifted remdesivir to an expanded access program. “We believe that the company's explanation is in line with Good Clinical Practice guidelines which recommend robust data collection and structured datasets, which one-off compassionate usage does not allow. We also believe GILD continues its manufacturing campaign for remdesivir (IV, lyophilized) and that 3-6 months should be enough to get to commercial scale manufacturing (from current clinical scale),” Singh commented. 

To this end, the Oppenheimer analyst stayed with the bulls. Along with his Outperform rating, Singh left the $80 price target as is, implying 10% upside potential. (To watch Singh’s track record, click here)  

Looking at the consensus breakdown, 10 Buys, 8 Holds and a single Sell add up to a Moderate Buy consensus rating. At $77.67, the average price target indicates modest upside potential of 7%. (See Gilead stock analysis on TipRanks)    

Regeneron Pharmaceuticals (REGN) 

As for Oppenheimer’s second pick, biotech colossus Regeneron has earned significant praise from the firm for its drug’s ability to be used as a possible defense against COVID-19. Notching a 19% year-to-date gain, the rest of the Street is also keeping an eye on REGN. 

Singh, who covers Gilead as well, highlights the potential of its anti-IL-6 agent Kevzara, which came as part of a collaboration with Sanofi, to be used as a last line COVID-19 treatment. The drug could reduce levels of IL-6, which are connected to higher mortality rates in pneumonia patients. This is encouraging as pneumonia symptoms are similar to the lung complications that occur in some severe COVID-19 patients. Sanofi and Regeneron are already initiating a Phase 2/3 trial evaluating Kevzara, and the implications could be monumental.  

If successful in clinical trials, the therapy could be used in about 15% patients. “Treatments such as anti-IL-6 agents (REGN/Sanofi's Kevzara and Roche's Actemra), could be a last line of therapy given that both are very powerful immunodulatory drugs, expensive and have non-trivial side effects themselves. Anti-IL-6 drugs might be prescribed to the sickest patients; experiencing multiple organ failure or acute respiratory disease syndrome (ARDS),” Singh noted. As a result, Singh kept an Outperform call and $525 price target on the stock. 

Meanwhile, Canaccord Genuity analyst John Newman notes that REGN is working on a two-antibody cocktail as a weapon against COVID-19, with initial clinical testing slated to start this summer. As Regeneron was able to successfully design a therapy for Ebola (REGN-EB3) that features the same technology, the future looks even brighter for the biotech, in the five-star analyst’s opinion.  

It also doesn’t hurt that its Dupixent, Libtayo and EYLEA products for patients with diabetes could drive some serious upside. In line with his optimistic take, Newman maintained a Buy recommendation and $550 price target. Should the target be met, a 22% twelve-month gain could be in the cards. (To watch Newman’s track record, click here)  

What does the rest of the Street have to say? Out of 15 analysts that have published a recent review, 9 rate the biotech as a Buy and 6 as a Hold, making the Street consensus a Moderate Buy. The $465 average price target brings the upside potential to 3%. (See Regeneron stock analysis on TipRanks)

It's raining gold. That's probably how Warren Buffett would summarize the stock market crash. Buffett wrote to Berkshire Hathaway shareholders in 2010: "Big opportunities come infrequently. When it's raining gold, reach for a bucket, not a thimble." 

What's Warren Buffett's favorite stock? That's a softball question, of course. The answer is indisputably Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), the company Buffet has led for over five decades.

It's a scary time to be an investor. Due to fears surrounding the COVID-19 pandemic, the stock market has been hammered over the past few weeks. On March 11, the Dow Jones slid by 5.9% and closed more than 20% down from its most recent all-time high, thus officially entering bea

Elon Musk is tweaking his space plans.

When it comes to retirement, you're well-served to remember the carpenter's rule: Measure twice, cut once. You don't want to claim your Social Security at age 62, for example, and then realize six months later you have to return to the workforce. Missteps like that can be costly

Medical marijuana in Germany, one of the world's top markets for that form of the drug, experienced a boom in 2019. Quoting statistics from the country's National Association of Statutory Health Insurance Funds, Marijuana Business Daily said that insurance companies reimbursed G

While markets are reeling from the rapid spread of COVID-19 and resulting economic disruption, investors are looking for save havens in which to park their funds. The broader markets are expected to be volatile in the near term until countries around the world come to grips with

Social distancing efforts have more people staying at home, and they're streaming a lot of video. In fact, consumer demand for streaming video may outpace what most consumers already have available in their lineup of subscription and ad-supported options. There's only so many ti

Just one-and-a-half months ago, shares of General Electric (NYSE: GE) touched a 52-week high as investors continued to gain confidence in the company's turnaround. 2019 was hardly a great year for the industrial conglomerate, as industrial free cash flow fell by nearly 50% year

Rapid testing for the novel coronavirus that's responsible for at least 100,000 cases of COVID-19 in the U.S. is getting an important upgrade. Abbott (NYSE: ABT) recently received an emergency use authorization (EUA) for a test that can provide results in just five minutes.  

The stock market has been showing signs of life over the past few days, but there are still many stocks trading near their 52-week lows. For investors, it's important to discern whether a stock at its low is a bargain or if it's due for an even bigger collapse around the corner.

Most retailers across the country have closed their stores because they've either been ordered to do so through state shelter-in-place orders or have voluntarily shut down to help contain the spread of the coronavirus. 

There's nothing quite like a hot pizza delivered right to your door. And there's nothing quite like the three-year 91% total shareholder return that Domino's Pizza (NYSE: DPZ) has delivered to investors, versus the 52% return of the S&P 500 over the same period.

If you threw a dart at a dartboard covered with every stock ticker on the market, the odds are overwhelmingly in favor of you hitting a stock that's down so far in 2020. Only a few have managed to rise in the midst of the massive meltdown caused by the novel coronavirus pandemic

The novel coronavirus pandemic has sent a shockwave across the globe, and people have changed the way they live in an attempt to fight the disease. That's leaving companies scurrying to adapt to the new environment, and sellers of consumer goods face particularly difficult chall

The COVID-19 outbreak has upended the global economy, causing stocks to plummet. Investors are selling off everything due to the uncertainty of when conditions will stabilize and we'll return to some sense of normal.

The coronavirus pandemic spreading around the world is leaving a wake of destruction in its path.